10 results
To evaluate safety of 3-months versus standard 12-months of DAPT
In the current study, we want to demonstrate Rienso uptake in the vessel wall in patients with cardiovascular disease and relate the uptake of Rienso to endothelial permeability.
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
Main objective:- To assess the tumor uptake of Zr89-labeled CER-001 (% injected dose/gram)Secondary objectives:- To evaluate the biodistribution of Z89r-labeled CER-001- To evaluate the correlation between Zr89-labeled CER-001 and tumor…
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
Primary Objectives: - Assess the feasibility and clinical value of 7T MR to provide a more detailed anatomic description of the anterior visual pathway in NFMA patients compared to conventional MRI. - Assess the feasibility of high-field MRI to…
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
The aim of this study is to evaluate and describe the PK of fosfomycin in individuals receiving oral treatment with multiple dosages of fosfomycin for recurrent and/or complicatedurinary tract infection. The results of this study will be used to…
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…